Sanjeevni Today

Zydus gets final approval for Cisatracurium Besylate Injection USP from USFDA

Sanjeevni Today 05-11-2019 03:01 PM

Zydus gets final approval for Cisatracurium Besylate Injection USP from USFDA


Mumbai. Pharma major, Zydus Cadila has received the final approval From the USFDA to market Cisatracurium Besylate Injection USP 10 mg (base)/5 mL (2 mg/mL) and 200 mg (base)/20 mL (10 mg/mL) Single-Dose Vials (Preservative-free)(US RLD - Nimbex).

Read this news also:Amid protest, Union Minister Rijiju bats for police, says "being a cop is a thankless job"

This medication is used to relax the muscles. It works by blocking the signals between one's nerves and one's muscles. This medicine is given before general anaesthesia in preparing for surgery, company said in a filing with BSE.

It will be manufactured at Liva Pharmaceuticals Limited, a wholly-owned subsidiary company of Cadila Healthcare Limited.

The group now has 275 approvals and has so far filed over 360 ANDAS since the commencement of the filing process in FY 2003-04.

More From Business

Trending Now